Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Danish drugmaker Novo Nordisk (NOV: N) has filed for European approval of a higher-dose version of its obesity treatment ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...